Description: Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetic and lysosomal diseases. The company offers Elocta to treat haemophilia A; and Alprolix to treat haemophilia B. It also provides Orfadin for the treatment of hereditary tyrosinaemia type 1; and Kineret for the treatment of auto inflammatory condition, as well as Xiapex to treat Dupuytren's contracture and Peyronie's disease. In addition, the company manufactures drug substance for ReFacto AF; and develops BIVV001 and BIVV002 for the treatment of hemophilia. It operates in Sweden, the Middle East, North Africa, Russia, North America, other European countries, and internationally. The company has an agreement with Bioverativ for the development and commercialization of Elocta and Alprolix, as well as XTEN-programs. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.
Home Page: www.sobi.com
Tomtebodavägen 23A
Solna,
112 76
Sweden
Phone:
46 86 97 20 00
Officers
| Name | Title |
|---|---|
| Dr. Guido Oelkers | CEO & Pres |
| Dr. Anders Ullman M.D., Ph.D. | Head of R&D & Medical Affairs and Chief Medical Officer |
| Mr. Henrik Stenqvist | Chief Financial Officer |
| Ms. Christine Wesstrom | Head of Technical Operations |
| Mr. Thomas Kudsk Larsen | Head of Communication & Investor Relations |
| Mr. Torbjörn Hallberg | Gen. Counsel and Head of Legal Affairs & HR |
| Mr. Daniel Rankin | Head of Strategy & Corp. Devel. |
| Pablo de Mora | Head of Global Marketing & Access |
| Mr. Philip Wood | Head of Haematology |
| Ms. Konstantina Karampela | Sr. Director of European Commercial Operations (Specialty Care and Partner Products) |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 16.6389 |
|---|---|
| Trailing PE: | 21.5816 |
| Price-to-Book MRQ: | 2.5801 |
| Price-to-Sales TTM: | 3.6805 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 1555 |